Sipka S, Szucs K, Szántó S, Kovács I, Lakos G, Kiss E, Antal-Szalmás P, Szegedi G, Gergely P
3rd Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4004 Debrecen, Hungary.
Ann Rheum Dis. 2001 Apr;60(4):380-4. doi: 10.1136/ard.60.4.380.
To compare the activity of calcineurin in the peripheral blood mononuclear cells (PBMC) of 32 patients with systemic lupus erythematosus (SLE) and 35 healthy controls.
The activity of calcineurin was assayed in the supernatants of sonicated mononuclear cells.
There was no significant difference in the calcineurin activity of patients with SLE not taking glucocorticosteroids (GCS) compared with the healthy controls. On the other hand, the activity of calcineurin was reduced in patients with SLE taking GCS, correlating negatively with the dose of GCS. The stimulation of PBMC by phorbol ester and calcium ionophore decreased the calcineurin activity both in patients with SLE and in healthy controls. GCS could also reduce calcineurin activity in the mononuclear cells of healthy subjects in vitro.
In patients with SLE the decrease in the calcineurin activity of PBMC depended on the dose of GCS used for treatment, and it was not a disease specific alteration. The higher the dose of GCS, the greater the inhibition of calcineurin activity. The reduction of calcineurin activity is a new element in the immunosuppressive effects of GCS during the treatment of patients with SLE.
比较32例系统性红斑狼疮（SLE）患者和35名健康对照者外周血单个核细胞（PBMC）中钙调神经磷酸酶的活性。
测定经超声处理的单个核细胞上清液中钙调神经磷酸酶的活性。
未服用糖皮质激素（GCS）的SLE患者的钙调神经磷酸酶活性与健康对照者相比无显著差异。另一方面，服用GCS的SLE患者的钙调神经磷酸酶活性降低，且与GCS剂量呈负相关。佛波酯和钙离子载体对PBMC的刺激可降低SLE患者和健康对照者的钙调神经磷酸酶活性。GCS在体外也可降低健康受试者单个核细胞中的钙调神经磷酸酶活性。
SLE患者PBMC中钙调神经磷酸酶活性的降低取决于用于治疗的GCS剂量，并非疾病特异性改变。GCS剂量越高，对钙调神经磷酸酶活性的抑制作用越大。钙调神经磷酸酶活性的降低是GCS治疗SLE患者时免疫抑制作用的一个新因素。
